Regeneron Pharmaceuticals
Nasdaq REGN · Tarrytown, NY
Works in Cardiovascular · Dermatology · ENT · Genetic & rare · GI & liver · Hematology · Immunology · Infectious disease · Metabolic & endocrine · Musculoskeletal · Neurology · Oncology · Ophthalmology · Psychiatry · Renal & urogenital · Respiratory · Women's health
Regeneron Pharmaceuticals is a clinical trial sponsor based in Tarrytown, NY, listed as Nasdaq REGN. It has 123 active clinical trials with 77,639 planned participants, across 17 therapeutic areas. Since 2021 it has completed 104 trials and stopped 44 early. Its FDA record on file shows 1 inspection.
Trial track record · since 2021
FDA record
Recent FDA actions
Financials · Nasdaq REGN
Pipeline · 123 active trials
| Stage | Trial | Status |
|---|---|---|
On the market
9 approved drug applications with a product on the market.
Questions about Regeneron Pharmaceuticals
No warning letter naming Regeneron Pharmaceuticals is on file. FDA has published 1 inspection classification naming it.
FDA has posted 1 inspection classification naming Regeneron Pharmaceuticals. The latest inspection ended on 2026-09-04 and was classified NAI (no action indicated). FDA posts a classification after its review, often months after the inspection ended.
Regeneron Pharmaceuticals is lead sponsor of 123 active clinical trials on ClinicalTrials.gov, with 77,639 planned participants, in Cardiovascular, Dermatology, ENT, Genetic & rare and other areas. Since 2021 it has completed 104 trials and stopped 44 early.
Regeneron Pharmaceuticals is based in Tarrytown, NY and is listed as Nasdaq REGN. The address is the one on its SEC filings, which name the establishment or the registrant, not always the group's head office.
From public sources only: ClinicalTrials.gov for trials, FDA's Data Dashboard, warning-letter listing and enforcement reports for the FDA record, and SEC filings for financials. Approve Suite is not affiliated with Regeneron Pharmaceuticals; every record links to the source, and nothing here is advice.
See the rest of this profile
A free account shows the trial list, the financials and the fundraising filings. Pro adds a watchlist: one email when FDA acts on a company you name.
Trial counts are as the sponsor reported them to ClinicalTrials.gov, for trials changed since 2021; latest update 2026-11-06.
The FDA record counts inspection classifications, warning letters and recalls FDA has published that name this company. Compare it with the industry in the free CDMO FDA inspection lookup.
Approve Suite is not affiliated with Regeneron Pharmaceuticals.
See something wrong on this page? Write to info@approvesuite.com and we will check it against the source. How corrections work.